X

Rubriques :

Maroc - ONCOLOGYNEWS.COM.AU - A La Une - 13/Sep 02:23

WCLC 2024: Perioperative nivolumab may provide meaningful improvement in event-free survival compared to only neoadjuvant nivolumab plus chemotherapy for resectable NSCLC

New data from landmark analysis presented today report a decreased risk of disease recurrence or death in patients with resectable NSCLC who received adjuvant nivolumab following neoadjuvant nivolumab plus chemotherapy and surgery compared to those who received only neoadjuvant nivolumab plus chemotherapy. The data was reported at the International Association for the Study of Lung [...]

Articles similaires

Perioperative Nivolumab Beneficial for Resectable NSCLC

drugs.com - 12/Sep 15:09

THURSDAY, Sept. 12, 2024 -- For patients with resectable non-small-cell lung cancer (NSCLC), perioperative nivolumab is associated with event-free...

WCLC 2024: NeoCOAST-2 Data shows combination of Durvalumab with novel agents increases pathological responses in resectable NSCLC — Data builds on AEGEAN study research

oncologynews.com.au - 15/Sep 05:24

Phase 2 results from the NeoCOAST-2 study demonstrated that the combination of durvalumab with Dato-DXd yielded the highest pathological complete...

WCLC 2024: NeoCOAST-2 Data shows combination of durvalumab with novel agents increases pathological responses in resectable NSCLC

oncologynews.com.au - 13/Sep 02:26

Phase 2 results from the NeoCOAST-2 study demonstrated that the combination of durvalumab with Dato-DXd yielded the highest pathological complete...

WCLC 2024: NeoCOAST-2 Data shows combination of durvalumab with novel agents increases pathological responses in resectable NSCLC

oncologynews.com.au - 13/Sep 02:26

Phase 2 results from the NeoCOAST-2 study demonstrated that the combination of durvalumab with Dato-DXd yielded the highest pathological complete...

WCLC 2024: PanCan nodule management protocol more effective than LungRADSv1.1 method

oncologynews.com.au - 13/Sep 02:22

New data presented today reveals that the PanCan nodule management protocol demonstrates superior performance in triaging lung cancer screening...

Pancreatic cancers change identity as they transform into aggressive types

oncologynews.com.au - 15/Sep 03:15

In contrast to other commonly diagnosed cancers like colorectal and lung cancer, the 5-year survival rate after diagnosis for pancreatic cancer is...

Datopotamab Deruxtecan Showed Median Overall Survival of 14.6 Months in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer in TROPION-Lung01 Phase III Trial

drugs.com - 09/Sep 09:09

9 September 2024 -- Detailed results from the TROPION-Lung01 Phase III trial showed a clinically meaningful trend toward improving overall survival...

Datopotamab Deruxtecan Showed Median Overall Survival of 14.6 Months in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer in TROPION-Lung01 Phase III Trial

drugs.com - 09/Sep 09:09

9 September 2024 -- Detailed results from the TROPION-Lung01 Phase III trial showed a clinically meaningful trend toward improving overall survival...

Tusamitamab Ravtansine Does Not Extend Survival With Nonsquamous NSCLC

drugs.com - 13/Sep 14:09

FRIDAY, Sept. 13, 2024 -- Tusamitamab ravtansine (tusa rav), an immunoconjugate, does not improve progression-free survival (PFS) in patients with...

PDX engraftment predicts high recurrence and poor survival in triple-negative breast cancer

news.medical.net - 11/Sep 08:56

Researchers examine the association between patient-derived xenograft with recurrence and survival rates in triple negative breast cancer patients.

Les derniers communiqués

Aucun élément